At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ICCM IceCure Medical Ltd.
Post-Market Trading 11-22 16:28:14 EST
0.7122
+0.1138
+19.02%
盘后0.6901
-0.0221-3.10%
16:27 EST
High0.7564
Low0.5910
Vol1.68M
Open0.5980
D1 Closing0.5984
Amplitude27.64%
Mkt Cap39.53M
Tradable Cap20.42M
Total Shares55.50M
T/O1.12M
T/O Rate5.85%
Tradable Shares28.68M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024
IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.